Using value based economics to evaluate competitive advantage of antifungal therapies in febrile neutropenia in BC

The Canadian health care system has faced unprecedented demands for its resources. The aging population, newer technologies and refined treatment protocols are examples of causes that drive up costs. Health care administrators are looking for ways to balance effective treatment outcomes and related treatment costs. In order for companies to compete in this business environment, a meaningful strategic partnership must be established to address the needs of the buyers and administrators. In the case of anti-fungal treatments relating to febrile neutropenia, this paper tries to demonstrate a sustainable competitive advantage of company M's product C by utilizing value based economic models. By taking the buyers' economic concerns into consideration, these models can address product C's two main business challenges: restricted product usage and competition.